GenVec, Inc.
(NASDAQ : GNVC)

( )
GNVC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 1.02%147.150.7%$951.23m
PFEPfizer Inc. 1.00%36.410.9%$876.74m
ABBVAbbVie, Inc. 1.23%87.291.9%$703.59m
MRKMerck & Co., Inc. -0.19%82.770.7%$700.22m
BMYBristol-Myers Squibb Co. 0.39%59.721.0%$664.00m
LLYEli Lilly & Co. -1.42%148.121.1%$561.16m
AZNAstraZeneca Plc -1.37%54.751.2%$254.11m
NVSNovartis AG -0.08%87.040.2%$164.14m
GSKGlaxoSmithKline Plc 0.16%37.860.2%$111.92m
PRNBPrincipia Biopharma, Inc. 0.00%100.050.0%$81.32m
NVONovo Nordisk A/S 0.17%69.180.1%$58.68m
RGENRepligen Corp. 2.07%147.287.1%$49.44m
RPRXRoyalty Pharma Plc 2.85%41.210.2%$48.51m
SNYSanofi 0.43%51.000.2%$46.13m
TPTXTurning Point Therapeutics, Inc. 3.05%89.330.0%$37.07m

Company Profile

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).